Atorvastatin: a Review of Its Use in the Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

Overview

Journal Drugs

Specialty Pharmacology

Date 2004 Dec 22

PMID 15610062

Citations 2

Authors

Katherine F Croom

Greg L Plosker

Affiliations

Soon will be listed here.

Abstract

Atorvastatin (Lipitor) is an HMG-CoA reductase inhibitor with well documented lipid-lowering effects. It has recently been evaluated for the primary prevention of major cardiovascular events in patients with type 2 diabetes mellitus without elevated serum low-density lipoprotein (LDL)-cholesterol levels. Atorvastatin 10mg daily for 4 years was effective at reducing the risk of a first major cardiovascular event, including stroke, in a large, placebo-controlled, multicentre trial in patients with type 2 diabetes and at least one other coronary heart disease (CHD) risk factor, but without markedly elevated LDL-cholesterol levels. In this trial, known as CARDS (the Collaborative AtoRvastatin Diabetes Study), atorvastatin had a similar tolerability profile to that of placebo. Thus, atorvastatin has a potential role in the primary prevention of cardiovascular events in diabetic patients at risk of CHD, irrespective of pre-treatment LDL-cholesterol levels.

Citing Articles

Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability.

Dennison T, Smith J, Badhan R, Mohammed A Drug Des Devel Ther. 2017; 11:811-826.

PMID: 28352156 PMC: 5358997. DOI: 10.2147/DDDT.S126035.

Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.

Curran M Drugs. 2010; 70(2):191-213.

PMID: 20108992 DOI: 10.2165/11204420-000000000-00000.

References

Graham D, Staffa J, Shatin D, Andrade S, Schech S, La Grenade L . Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004; 292(21):2585-90. DOI: 10.1001/jama.292.21.2585. View

Soedamah-Muthu S, Colhoun H, Thomason M, Betteridge D, Durrington P, Hitman G . The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis. 2003; 167(2):243-55. DOI: 10.1016/s0021-9150(02)00428-8. View

. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care. 2001; 24(8):1335-41. DOI: 10.2337/diacare.24.8.1335. View

Haverkate F, Thompson S, Pyke S, Gallimore J, Pepys M . Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997; 349(9050):462-6. DOI: 10.1016/s0140-6736(96)07591-5. View

Schartl M, Bocksch W, Koschyk D, Voelker W, Karsch K, Kreuzer J . Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001; 104(4):387-92. DOI: 10.1161/hc2901.093188. View

van Tits L, Smilde T, van Wissen S, de Graaf J, Kastelein J, Stalenhoef A . Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial.... J Investig Med. 2004; 52(3):177-84. DOI: 10.1136/jim-52-03-32. View

Davidson M, GOLDSTEIN R, Davignon J, Isaacsohn J, Weiss S, Keilson L . Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996; 275(2):128-33. View

Ford I, Singh T, Kitchen S, Makris M, Ward J, Preston F . Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. Diabet Med. 1991; 8(4):322-9. DOI: 10.1111/j.1464-5491.1991.tb01604.x. View

Taylor A, Kent S, Flaherty P, Coyle L, Markwood T, Vernalis M . ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002; 106(16):2055-60. DOI: 10.1161/01.cir.0000034508.55617.65. View

10.

Garg A . Statins for all patients with type 2 diabetes: not so soon. Lancet. 2004; 364(9435):641-2. DOI: 10.1016/S0140-6736(04)16907-9. View

11.

Colhoun H, Betteridge D, Durrington P, Hitman G, Neil H, Livingstone S . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435):685-96. DOI: 10.1016/S0140-6736(04)16895-5. View

12.

Economides P, Caselli A, Tiani E, Khaodhiar L, Horton E, Veves A . The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab. 2004; 89(2):740-7. DOI: 10.1210/jc.2003-031116. View

13.

Nissen S, Tuzcu E, Schoenhagen P, Brown B, Ganz P, Vogel R . Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291(9):1071-80. DOI: 10.1001/jama.291.9.1071. View

14.

Berk-Planken I, Hoogerbrugge N, Stolk R, Bootsma A, Jansen H . Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant. Diabetes Care. 2003; 26(2):427-32. DOI: 10.2337/diacare.26.2.427. View

15.

Karaca I, Ilkay E, Akbulut M, Yavuzkir M, Pekdemir M, Akbulut H . Atorvastatin affects C-reactive protein levels in patients with coronary artery disease. Curr Med Res Opin. 2003; 19(3):187-91. DOI: 10.1185/030079903125001686. View

16.

Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini A . Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol. 2000; 36(5):617-21. DOI: 10.1097/00005344-200011000-00011. View

17.

Haffner S . Dyslipidemia management in adults with diabetes. Diabetes Care. 2003; 27 Suppl 1:S68-71. DOI: 10.2337/diacare.27.2007.s68. View

18.

Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H . Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004; 110(9):1061-8. DOI: 10.1161/01.CIR.0000140261.58966.A4. View

19.

Almdal T, Scharling H, Skov Jensen J, Vestergaard H . The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004; 164(13):1422-6. DOI: 10.1001/archinte.164.13.1422. View

20.

van de Ree M, Huisman M, Princen H, Meinders A, Kluft C . Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 2002; 166(1):129-35. DOI: 10.1016/s0021-9150(02)00316-7. View